|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,336.00 GBX | -1.33% |
|
+3.02% | +11.36% |
| 05:13am | Astra Zeneca and Svolder Trade Ex-Dividend Today on Nasdaq Stockholm | FW |
| 04:44am | UK Stocks-Factors to watch on February 19 | RE |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 131,259 | 182,034 | 209,442 | 209,268 | 203,171 | 326,543 | 326,543 | - |
| Change | - | 38.68% | 15.06% | -0.08% | -2.91% | 60.72% | 0% | - |
| Enterprise Value (EV) 1 | 143,126 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 345,229 | 337,709 |
| Change | - | 44.22% | 12.57% | -0.25% | -1.74% | 36.64% | -0.92% | -2.18% |
| P/E ratio | 41x | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 26.7x | 23.4x |
| PBR | 8.4x | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 6.13x | 5.38x |
| PEG | - | -15.2x | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.7x |
| Capitalization / Revenue | 4.93x | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 5.22x | 4.91x |
| EV / Revenue | 5.38x | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 5.52x | 5.08x |
| EV / EBITDA | 17.2x | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 15.3x | 13.6x |
| EV / EBIT | 19.5x | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 16.4x | 14.4x |
| EV / FCF | 37.3x | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 32x | 25.1x |
| FCF Yield | 2.68% | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.12% | 3.98% |
| Dividend per Share 2 | 2.8 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.329 | 3.54 |
| Rate of return | 2.8% | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 1.58% | 1.68% |
| EPS 2 | 2.44 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.887 | 8.99 |
| Distribution rate | 115% | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.2% | 39.4% |
| Net sales 1 | 26,617 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 62,545 | 66,462 |
| EBITDA 1 | 8,311 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,616 | 24,801 |
| EBIT 1 | 7,340 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,083 | 23,382 |
| Net income 1 | 3,196 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,428 | 14,088 |
| Net Debt 1 | 11,867 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 18,686 | 11,166 |
| Reference price 2 | 99.99 | 117.51 | 135.16 | 135.02 | 131.05 | 210.54 | 210.54 | 210.54 |
| Nbr of stocks (in thousands) | 1,312,660 | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,945 | 1,550,945 | - |
| Announcement Date | 11/02/21 | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | 10/02/26 | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.2x | 5.94x | 17.72x | 1.54% | 327B | |
| 30.34x | 11.55x | 23.19x | 0.65% | 912B | |
| 24.94x | 6.05x | 16.47x | 2.16% | 590B | |
| 63.86x | 7.56x | 18.72x | 2.86% | 404B | |
| 19.56x | 4.81x | 11.93x | 2.72% | 382B | |
| 21.82x | 6.06x | 14.9x | 2.66% | 315B | |
| 15.71x | 5.04x | 10.99x | 2.65% | 302B | |
| 14.84x | 5.14x | 10.78x | 3.49% | 219B | |
| 25.66x | 6.45x | 11.33x | 2.64% | 205B | |
| 22.4x | 6.93x | 12.67x | 2.17% | 190B | |
| Average | 27.23x | 6.55x | 14.87x | 2.36% | 384.43B | |
| Weighted average by Cap. | 28.84x | 7.32x | 16.61x | 2.06% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition